Nanomedicine Research Journal

Nanomedicine Research Journal

Preventive Effect of ZnO-Metformin Nanocomposite Against Carbon Tetrachloride-Induced Hepatotoxicity

Document Type : Original Research Article

Authors
Fatemeh Adibipour 1
Mahsa Salehirad 1
A.Wallace Hayes 2, 3
Malak Hekmati 4
Majid Motaghinejad 5
1 Department of Organic Chemistry, Faculty of Pharmaceutical Chemistry, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
2 Institute for Integrative Toxicology, Michigan State University, East Lansing, MI, USA
3 Center for Environmental Occupational Risk Analysis and Management, College of Public Health, University of South Florida, Tampa, FL, USA
4 Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Chemistry, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
5 Chronic Respiratory Disease Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
10.22034/nmrj.2024.02.004
Abstract
Objective(s): The protective effect of metformin on liver disorders has been reported . Studies have documented the hepatoprotective benefits of metformin against liver disorders, but due to its low bioavailability and untoward side effects, metformin has limited therapeutic utility. Nanotechnology has increased efficiency and reduced the side effects of several drugs
Methods: A ZnO-metformin nanocomposite was synthesized. The protective effects of metformin (150 mg/kg), ZnO (10 mg/kg), and the ZnO-metformin nanocomposite (50, 100, 150 mg/kg) were compared in a CCl4-induced hepatocellular damaged mouse model. Serum liver enzymes, oxidative stress biomarkers, and histological changes in hepatocytes were evaluated.
Results: The levels of AST, ALT and ALP in the blood were prevented by the metformin and ZnO-metformin nanocomposite against the action of CCl4, as well as liver damage associated with it. Furthermore, metformin or/and ZnO-metformin nanocomposite reversed the SOD, GPx and GR activity that was found to be lowered due to CCl4, as well as increased MDA levels under the same condition. The extent of hepatoprotection with respect to the two agents in question also differed significantly in terms of dose. The ZnO-metformin nanocomposite hepatoprotective effects occurred at lower doses than metformin.  ZnO alone did not alter the CCl4-induced hepatic injury.
Conclusions: The ZnO-metformin nanocomposite was a more efficient hepatoprotective agent at lower doses than metformin. The ZnO-metformin nanocomposite has the potential to be a replacement for metformin as a hepatoprotective drug candidate.
Keywords
Metformin
ZnO-metformin Nanocomposite
Liver Injury
Carbon Tetrachloride

Subjects

  1. Bhat, A., G. Sebastiani, and M. Bhat, Systematic review: Preventive and therapeutic applications of metformin in liver disease. World journal of hepatology, 2015. 7(12): p. 1652. https://doi.org/10.4254/wjh.v7.i12.1652
  2. Li, Y., et al., Metformin in non-alcoholic fatty liver disease: A systematic review and meta‑analysis. Biomedical reports, 2013. 1(1): p. 57-64. https://doi.org/10.3892/br.2012.18
  3. Jaeschke, H., Toxic responses of the liver. Casarett's & Doull's Toxicology: The Basic Science of Poisoning, 2008: p. 557-582.
  4. Dong, S., et al., Mechanisms of CCl4-induced liver fibrosis with combined transcriptomic and proteomic analysis. The Journal of toxicological sciences, 2016. 41(4): p. 561-572. https://doi.org/10.2131/jts.41.561
  5. Poon, M.K., et al., Metformin protects against carbon tetrachloride hepatotoxicity in mice. Journal of pharmacological sciences, 2003. 93(4): p. 501-504. https://doi.org/10.1254/jphs.93.501
  6. Salehi, E., et al., Curcumin can be acts as effective agent for prevent or treatment of alcohol-induced toxicity in hepatocytes: an illustrated mechanistic review. Iranian Journal of Pharmaceutical Research: IJPR, 2021. 20(1): p. 418.
  7. Ullah, H., et al., Poncirin attenuates CCL4-induced liver injury through inhibition of oxidative stress and inflammatory cytokines in mice. BMC complementary medicine and therapies, 2020. 20(1): p. 1-14. https://doi.org/10.1186/s12906-020-02906-7
  8. Hosny, K.M., N.A. Alhakamy, and K.S. Al Nahyah, The relevance of nanotechnology, hepato-protective agents in reducing the toxicity and augmenting the bioavailability of isotretinoin. Drug Delivery, 2021. 28(1): p. 115-125. https://doi.org/10.1080/10717544.2020.1862365
  9. Aboubakr, E.M., et al., Glutathione-loaded non-ionic surfactant niosomes: A new approach to improve oral bioavailability and hepatoprotective efficacy of glutathione. Nanotechnology Reviews, 2021. 11(1): p. 117-137. https://doi.org/10.1515/ntrev-2022-0010
  10. Al Nahyah, K.S.A., Utilization of Nanotechnology and Hepatoprotective Agents to Improve the Bioavailability and to Reduce the Toxicity Associated with Isotretinoin. 2021, KING ABDULAZIZ UNIVERSITY JEDDAH.
  11. Iranshahy, M., R. Rezaee, and G. Karimi, Hepatoprotective activity of metformin: a new mission for an old drug? European journal of pharmacology, 2019. 850: p. 1-7. https://doi.org/10.1016/j.ejphar.2019.02.004
  12. Keshavarzi, S., et al., Protective role of metformin against methamphetamine induced anxiety, depression, cognition impairment and neurodegeneration in rat: the role of CREB/BDNF and Akt/GSK3 signaling pathways. Neurotoxicology, 2019. 72: p. 74-84. https://doi.org/10.1016/j.neuro.2019.02.004
  13. Karami, F., et al., Is metformin neuroprotective against diabetes mellitus-induced neurodegeneration? An updated graphical review of molecular basis. Pharmacological Reports, 2023. 75(3): p. 511-543. https://doi.org/10.1007/s43440-023-00469-1
  14. Cozma, G.V., et al., In Vitro and In Ovo Evaluation of the Potential Hepatoprotective Effect of Metformin. Medicina, 2022. 58(6): p. 705. https://doi.org/10.3390/medicina58060705
  15. El-Beheiry, K.M., et al., Combination of metformin and hesperidin mitigates cyclophosphamide-induced hepatotoxicity. Emerging role of PPAR-γ/Nrf-2/NF-κB signaling pathway. International Immunopharmacology, 2023. 117: p. 109891. https://doi.org/10.1016/j.intimp.2023.109891
  16. Sahu, T., et al., Nanotechnology based drug delivery system: Current strategies and emerging therapeutic potential for medical science. Journal of Drug Delivery Science and Technology, 2021. 63: p. 102487. https://doi.org/10.1016/j.jddst.2021.102487
  17. Kesharwani, S.S., et al., An overview of advanced formulation and nanotechnology-based approaches for solubility and bioavailability enhancement of silymarin. Journal of Drug Delivery Science and Technology, 2020. 60: p. 102021. https://doi.org/10.1016/j.jddst.2020.102021
  18. Abdussalam-Mohammed, W., Review of therapeutic applications of nanotechnology in medicine field and its side effects. Journal of Chemical Reviews, 2019. 1(3): p. 243-251. https://doi.org/10.33945/SAMI/JCR.2019.3.5
  19. Kamboj, V.K. and P.K. Verma, Preparation and characterization of metformin loaded Stearic Acid coupled F127 Nanoparticles. Asian J Pharm Clin Res, 2018. 11(8): p. 212-217. https://doi.org/10.22159/ajpcr.2018.v11i8.26444
  20. Shariatinia, Z. and Z. Zahraee, Controlled release of metformin from chitosan-based nanocomposite films containing mesoporous MCM-41 nanoparticles as novel drug delivery systems. Journal of colloid and interface science, 2017. 501: p. 60-76. https://doi.org/10.1016/j.jcis.2017.04.036
  21. Ghosh, M., et al., Synthesis and characterization of metformin conjugated magnetic nanocomposite with enhanced activity against the human carcinoma cells. Journal of Drug Delivery Science and Technology, 2023. 87: p. 104781. https://doi.org/10.1016/j.jddst.2023.104781
  22. Mobinhosseini, F., et al., Curcumin‐ZnO conjugated nanoparticles confer neuroprotection against ketamine‐induced neurotoxicity. Journal of Biochemical and Molecular Toxicology, 2024. 38(1): p. e23611. https://doi.org/10.1002/jbt.23611
  23. Percie du Sert, N., et al., The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. Journal of Cerebral Blood Flow & Metabolism, 2020. 40(9): p. 1769-1777. https://doi.org/10.1177/0271678X20943823
  24. Mehrafza, S., et al., Pharmacological evidence for lithium-induced neuroprotection against methamphetamine-induced neurodegeneration via Akt-1/GSK3 and CREB-BDNF signaling pathways. Iranian Journal of Basic Medical Sciences, 2019. 22(8): p. 856.
  25. Motaghinejad, M., et al., Molecular, histological and behavioral evidences for neuroprotective effects of minocycline against nicotine-induced neurodegeneration and cognition impairment: Possible role of CREB-BDNF signaling pathway. Behavioural Brain Research, 2020. 386: p. 112597. https://doi.org/10.1016/j.bbr.2020.112597
  26. Motaghinejad, M., et al., The possible role of CREB‐BDNF signaling pathway in neuroprotective effects of minocycline against alcohol‐induced neurodegeneration: molecular and behavioral evidences. Fundamental & Clinical Pharmacology, 2021. 35(1): p. 113-130. https://doi.org/10.1111/fcp.12584
  27. Ahmadinasab, H., et al., Hepato-Protection effect of curcumin against methylphenidate-induced hepatotoxicity: Histological and biochemical evidences. International Journal of Preventive Medicine, 2022. 13(1): p. 65. https://doi.org/10.4103/ijpvm.IJPVM_435_20
  28. Khokhar, N., Serum aminotransferase levels and platelet count as predictive factor of fibrosis and cirrhosis in patients with chronic hepatitis C infection. JOURNAL-PAKISTAN MEDICAL ASSOCIATION, 2003. 53(3): p. 101-103.
  29. Pohl, A., et al., Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. The American journal of gastroenterology, 2001. 96(11): p. 3142. https://doi.org/10.1016/S0002-9270(01)03830-8
  30. Mukaiyama, K., et al., Elevation of serum alkaline phosphatase (ALP) level in postmenopausal women is caused by high bone turnover. Aging clinical and experimental research, 2015. 27: p. 413-418. https://doi.org/10.1007/s40520-014-0296-x
  31. Feizipour, S., et al., Selegiline acts as neuroprotective agent against methamphetamine-prompted mood and cognitive related behavior and neurotoxicity in rats: Involvement of CREB/BDNF and Akt/GSK3 signal pathways. Iranian Journal of Basic Medical Sciences, 2020. 23(5): p. 606.
  32. Bancroft, J.D. and C. Layton, The hematoxylins and eosin. Bancroft's theory and practice of histological techniques, 2012. 7: p. 173-186. https://doi.org/10.1016/B978-0-7020-4226-3.00010-X
  33. Cardiff, R.D., C.H. Miller, and R.J. Munn, Manual hematoxylin and eosin staining of mouse tissue sections. Cold Spring Harbor Protocols, 2014. 2014(6): p. pdb. prot073411. https://doi.org/10.1101/pdb.prot073411
  34. Gu, X. and J.E. Manautou, Molecular mechanisms underlying chemical liver injury. Expert reviews in molecular medicine, 2012. 14: p. e4. https://doi.org/10.1017/S1462399411002110
  35. Yan, Y., et al., Combination of metformin and luteolin synergistically protects carbon tetrachloride‐induced hepatotoxicity: Mechanism involves antioxidant, anti‐inflammatory, antiapoptotic, and Nrf2/HO‐1 signaling pathway. Biofactors, 2019. 45(4): p. 598-606. https://doi.org/10.1002/biof.1521
  36. Meshkani, S., et al., Metformin as a protective agent against natural or chemical toxicities: a comprehensive review on drug repositioning. Journal of endocrinological investigation, 2020: p. 1-19. https://doi.org/10.1007/s40618-019-01060-3
  37. Madrigal-Santillán, E., et al., Review of natural products with hepatoprotective effects. World journal of gastroenterology: WJG, 2014. 20(40): p. 14787. https://doi.org/10.3748/wjg.v20.i40.14787
  38. Ganesan, K., M. Jayachandran, and B. Xu, A critical review on hepatoprotective effects of bioactive food components. Critical reviews in food science and nutrition, 2018. 58(7): p. 1165-1229. https://doi.org/10.1080/10408398.2016.1244154
  39. Ohnishi, S., H. Mizutani, and S. Kawanishi, The enhancement of oxidative DNA damage by anti-diabetic metformin, buformin, and phenformin, via nitrogen-centered radicals. Free Radical Research, 2016. 50(8): p. 929-937. https://doi.org/10.1080/10715762.2016.1204651
  40. Nakatake, R., et al., Metformin inhibits expression of the proinflammatory biomarker inducible nitric oxide synthase in hepatocytes. Functional Foods in Health and Disease, 2018. 8(3): p. 175-192. https://doi.org/10.31989/ffhd.v8i3.423
  41. Rostamkalaei, S.S., et al., Topical gel of Metformin solid lipid nanoparticles: A hopeful promise as a dermal delivery system. Colloids and Surfaces B: Biointerfaces, 2019. 175: p. 150-157. https://doi.org/10.1016/j.colsurfb.2018.11.072
  42. Elgogary, A., et al., Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer. Proceedings of the National Academy of Sciences, 2016. 113(36): p. E5328-E5336. https://doi.org/10.1073/pnas.1611406113
  43. Chinnaiyan, S.K., K. Deivasigamani, and V.R. Gadela, Combined synergetic potential of metformin loaded pectin-chitosan biohybrids nanoparticle for NIDDM. International journal of biological macromolecules, 2019. 125: p. 278-289. https://doi.org/10.1016/j.ijbiomac.2018.12.009
  44. Xu, Q., et al., Characterization and evaluation of metformin-loaded solid lipid nanoparticles for celluar and mitochondrial uptake. Drug development and industrial pharmacy, 2016. 42(5): p. 701-706. https://doi.org/10.3109/03639045.2015.1075028
  45. Arcaini, L., et al., Impact of treatment‐related liver toxicity on the outcome of HCV‐positive non‐Hodgkin's lymphomas. American journal of hematology, 2010. 85(1): p. 46-50. https://doi.org/10.1002/ajh.21564
  46. Lasley, F.D., et al., Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. Practical radiation oncology, 2015. 5(5): p. e443-e449. https://doi.org/10.1016/j.prro.2015.02.007
  47. Omar, Z., et al. Metformin versus silymarin as hepatoprotective agents in mice fibrotic model caused by carbon tetrachloride. in Annales Pharmaceutiques Françaises. 2022. Elsevier. https://doi.org/10.1016/j.pharma.2022.01.005
  48. Beheshti, F., et al., Ameliorative role of metformin on lipopolysaccharide-mediated liver malfunction through suppression of inflammation and oxidative stress in rats. Toxin Reviews, 2022. 41(1): p. 55-63. https://doi.org/10.1080/15569543.2020.1833037
  49. Gad, S.S., et al., Nanotechnology applications for treatment of hepatic infections via modulating Hepatic histopathological and DNA alterations. Bioorganic Chemistry, 2022. 127: p. 105927. https://doi.org/10.1016/j.bioorg.2022.105927
Nanomedicine Research Journal
Volume 9, Issue 2
Spring 2024
Pages 155-163